These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8988124)

  • 1. Occlusive paromomycin for cutaneous leishmaniasis.
    Bell SA; Schaller M; Röcken M
    Lancet; 1997 Jan; 349(9044):29. PubMed ID: 8988124
    [No Abstract]   [Full Text] [Related]  

  • 2. Occlusive paromomycin for cutaneous leishmaniasis.
    Bryceson AD
    Lancet; 1997 May; 349(9063):1477. PubMed ID: 9164342
    [No Abstract]   [Full Text] [Related]  

  • 3. Allergic contact dermatitis caused by paromomycin.
    Veraldi S; Benzecry V; Faraci AG; Nazzaro G
    Contact Dermatitis; 2019 Nov; 81(5):393-394. PubMed ID: 31231805
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z; Nakhli A; Rassaii S
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of cutaneous leishmaniasis with 20% paromomycin ointment.
    Stanimirović A; Stipić T; Skerlev M; Basta-Juzbasić A
    J Eur Acad Dermatol Venereol; 1999 Nov; 13(3):214-7. PubMed ID: 10642059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous leishmaniasis treatment.
    Minodier P; Parola P
    Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial.
    Soto J; Soto P; Ajata A; Luque C; Tintaya C; Paz D; Rivero D; Berman J
    Clin Infect Dis; 2019 Feb; 68(5):844-849. PubMed ID: 30260376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B; Abbaszadeh B; Khamesipour A
    Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluconazole for the treatment of cutaneous leishmaniasis.
    Zvulunov A; Klaus S; Vardy D
    N Engl J Med; 2002 Aug; 347(5):370-1; author reply 370-1. PubMed ID: 12151480
    [No Abstract]   [Full Text] [Related]  

  • 10. [Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)].
    Schallreuter KU; Lemke KR
    Hautarzt; 1994 Nov; 45(11):783-6. PubMed ID: 7822205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unsuccessful treatment of cutaneous leishmaniasis by Leishmania infantum with topical paromomycin.
    Veraldi S; Benzecry Mancin V; Faraci AG; Nazzaro G
    Int J Dermatol; 2020 Jul; 59(7):e251-e252. PubMed ID: 31975375
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful Treatment of Cutaneous Leishmaniasis with Topical Paramomycin in a Child After Treatment Failure with Systemic Fluconazole.
    Chacko A; Joseph M; Feltis T; Morris SK
    Am J Trop Med Hyg; 2016 Oct; 95(4):793-794. PubMed ID: 27549634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
    Krause G; Kroeger A
    Clin Infect Dis; 1999 Aug; 29(2):466-7. PubMed ID: 10476776
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran.
    Asilian A; Jalayer T; Nilforooshzadeh M; Ghassemi RL; Peto R; Wayling S; Olliaro P; Modabber F
    Bull World Health Organ; 2003; 81(5):353-9. PubMed ID: 12856053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
    Grogl M; Schuster BG; Ellis WY; Berman JD
    J Parasitol; 1999 Apr; 85(2):354-9. PubMed ID: 10219319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study.
    Pandey K; Pal B; Das VNR; Murti K; Lal CS; Verma N; Bimal S; Ali V; Verma RB; Topno RK; Siddiqi NA; Das P
    Br J Dermatol; 2017 Aug; 177(2):557-559. PubMed ID: 27781268
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin.
    Neva FA; Ponce C; Ponce E; Kreutzer R; Modabber F; Olliaro P
    Trans R Soc Trop Med Hyg; 1997; 91(4):473-5. PubMed ID: 9373659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmaniasis chemotherapy--challenges and opportunities.
    Croft SL; Olliaro P
    Clin Microbiol Infect; 2011 Oct; 17(10):1478-83. PubMed ID: 21933306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous Leishmaniasis in an American Adolescent Returning From Israel.
    Ganjaei KG; Lawton K; Gaur S
    J Pediatric Infect Dis Soc; 2018 Aug; 7(3):e178-e181. PubMed ID: 29878238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Topical treatment of persistent cutaneous leishmaniasis with paromomycin].
    Flaig MJ; Rupec J; Ruzicka T; Rupec RA
    Hautarzt; 2007 Aug; 58(8):689-90, 692. PubMed ID: 17676349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.